Literature DB >> 26110493

Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses.

Thomas H P Draak1, Els K Vanhoutte2, Sonja I van Nes3, Kenneth C Gorson4, W-Ludo Van der Pol5, Nicolette C Notermans5, Eduardo Nobile-Orazio6, Richard A Lewis7, Jean-Marc Léger8, Peter Y K Van den Bergh9, Giuseppe Lauria10, Vera Bril11, Hans Katzberg11, Michael P T Lunn12, Jean Pouget13, Anneke J van der Kooi14, Angelika F Hahn15, Leonard H van den Berg5, Pieter A van Doorn3, David R Cornblath16, Catharina G Faber1, Ingemar S J Merkies1,17.   

Abstract

We performed a comparison between Neuropathy Impairment Scale-sensory (NISs) vs. the modified Inflammatory Neuropathy Cause and Treatment sensory scale (mISS), and NIS-motor vs. the Medical Research Council sum score in patients with Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and IgM monoclonal gammopathy of undetermined significance-related polyneuropathy (MGUSP). The ordinal data were subjected to Rasch analyses, creating Rasch-transformed (RT)-intervals for all measures. Comparison between measures was based on validity/reliability with an emphasis on responsiveness (using the patient's level of change related to the individually obtained varying SE for minimum clinically important difference). Eighty stable patients (GBS: 30, CIDP: 30, and MGUSP: 20) were assessed twice (entry: two observers; 2-4 weeks later: one observer), and 137 newly diagnosed or relapsing patients (GBS: 55, CIDP: 59, and IgM-MGUSP: 23) were serially examined with 12 months follow-up. Data modifications were needed to improve model fit for all measures. The sensory and motor scales demonstrated approximately equal and acceptable validity and reliability scores. Responsiveness scores were poor but slightly higher in RT-mISS compared to RT-NISs. Responsiveness was equal for the RT-motor scales, but higher in GBS compared to CIDP; responsiveness was poor in patients with MGUSP, suggesting a longer duration of follow-up in the latter group of patients.
© 2015 Peripheral Nerve Society.

Entities:  

Keywords:  MRC; NIS; Rasch; mISS; responsiveness

Mesh:

Year:  2015        PMID: 26110493     DOI: 10.1111/jns.12127

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  4 in total

1.  Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Ivo Bozovic; Aleksandra Kacar; Stojan Peric; Ana Nikolic; Bogdan Bjelica; Mina Cobeljic; Milutin Petrovic; Aleksandar Stojanov; Vanja Djuric; Miroslav Stojanovic; Gordana Djordjevic; Vesna Martic; Aleksandra Dominovic; Zoran Vukojevic; Ivana Basta
Journal:  J Neurol       Date:  2017-10-30       Impact factor: 4.849

2.  Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.

Authors:  Ellen M Lavoie Smith; Noah Zanville; Grace Kanzawa-Lee; Clare Donohoe; Celia Bridges; Charles Loprinzi; Jennifer Le-Rademacher; James J Yang
Journal:  Support Care Cancer       Date:  2018-11-20       Impact factor: 3.603

3.  Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.

Authors:  Ingemar S J Merkies; John-Philip Lawo; Jonathan M Edelman; Jan L De Bleecker; Claudia Sommer; Wim Robberecht; Mika Saarela; Jerzy Kamienowski; Zbigniew Stelmasiak; Orell Mielke; Björn Tackenberg; Jean-Marc Léger
Journal:  J Peripher Nerv Syst       Date:  2017-06       Impact factor: 3.494

4.  Development of grading scales of pedal sensory loss using Mokken scale analysis on the Rotterdam Diabetic Foot Study Test Battery data.

Authors:  Willem D Rinkel; M Hosein Aziz; Johan W Van Neck; Manuel Castro Cabezas; L Andries van der Ark; J Henk Coert
Journal:  Muscle Nerve       Date:  2019-07-24       Impact factor: 3.217

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.